Core Insights - The article highlights the potential of FXI-targeted drugs to provide safer anticoagulation options without significantly increasing bleeding risks, with multiple drugs expected to enter critical data readout phases starting in 2026 [1][2] Market Overview - The global market for anticoagulant drugs reached $52.9 billion in 2023 and is projected to exceed $110 billion by 2033, driven by the aging population and rising cardiovascular disease prevalence [1] - The demand for anticoagulant drugs is steadily increasing, particularly in China, which lays a solid foundation for the development and commercialization of new anticoagulant drugs [1] Drug Development Trends - Traditional anticoagulants face challenges in balancing efficacy and bleeding risks, leading to the emergence of new oral anticoagulants (NOACs) that have improved upon the limitations of warfarin [1] - Major NOACs like Bayer's Xarelto (rivaroxaban) and BMS/Pfizer's Eliquis (apixaban) have achieved sales exceeding $1 billion, but still cannot avoid bleeding complications [1] - The expiration of core patents for these drugs will allow generics to enter the market, prompting a necessary shift towards the development and iteration of next-generation anticoagulants [1] FXI as a Target - FXI is identified as a key factor in pathological thrombosis, with studies showing that individuals with hereditary FXI deficiency have a significantly lower incidence of thrombotic events without a notable increase in spontaneous bleeding risk [2] - FXI inhibitors are being developed through various technological routes, including small molecules, monoclonal antibodies, and siRNA, targeting multiple indications such as atrial fibrillation, stroke prevention, and venous thromboembolism [2] Clinical Trials and Progress - Bayer's Asundexian has shown mixed results in pivotal Phase III trials, while BMS/Johnson & Johnson's Milvexian has faced challenges in its clinical trials [2] - Novartis's Abelacimab has received FDA fast track designation for two indications and is advancing in Phase III trials, while Regeneron's dual pipeline of FXI monoclonal antibodies is also in Phase III [2] - siRNA drugs are being explored for longer-lasting and safer treatment options, with companies like Ribopharma and Jingyin Pharmaceuticals making progress in Phase II studies [2]